Cargando…

Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists

BACKGROUND: The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient's lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of th...

Descripción completa

Detalles Bibliográficos
Autores principales: Volpi, Sonia, Carnovale, Vincenzo, Colombo, Carla, Raia, Valeria, Blasi, Francesco, Pappagallo, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169509/
https://www.ncbi.nlm.nih.gov/pubmed/35677472
http://dx.doi.org/10.1002/hsr2.604
_version_ 1784721223017562112
author Volpi, Sonia
Carnovale, Vincenzo
Colombo, Carla
Raia, Valeria
Blasi, Francesco
Pappagallo, Giovanni
author_facet Volpi, Sonia
Carnovale, Vincenzo
Colombo, Carla
Raia, Valeria
Blasi, Francesco
Pappagallo, Giovanni
author_sort Volpi, Sonia
collection PubMed
description BACKGROUND: The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient's lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients. METHOD: A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF. RESULTS: Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice. CONCLUSIONS: The consensus reached on a number of topics regarding use of mucoactive agents in patients with CF can help guide clinicians in daily practice based on expert experience and define the most appropriate therapeutic strategy for the individual patient.
format Online
Article
Text
id pubmed-9169509
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-91695092022-06-07 Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists Volpi, Sonia Carnovale, Vincenzo Colombo, Carla Raia, Valeria Blasi, Francesco Pappagallo, Giovanni Health Sci Rep Reviews BACKGROUND: The goal of mucoactive therapies in cystic fibrosis (CF) is to enhance sputum clearance and to reduce a progressive decline in lung function over the patient's lifetime. We aimed to investigate the level of consensus among specialists from Italian CF Centers on appropriateness of therapeutic use of dornase alfa (rhDNase) for CF patients. METHOD: A consensus on appropriate prescribing in CF mucoactive agents was appraised by an online Delphi method, based on a panel of 27 pulmonologists, coordinated by a Scientific Committee of six experts in medical care of patients with CF. RESULTS: Full or very high consensus was reached on several issues related to therapeutic use of dornase alfa for CF patients in clinical practice. CONCLUSIONS: The consensus reached on a number of topics regarding use of mucoactive agents in patients with CF can help guide clinicians in daily practice based on expert experience and define the most appropriate therapeutic strategy for the individual patient. John Wiley and Sons Inc. 2022-06-06 /pmc/articles/PMC9169509/ /pubmed/35677472 http://dx.doi.org/10.1002/hsr2.604 Text en © 2022 The Authors. Health Science Reports published by Wiley Periodicals LLC. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Reviews
Volpi, Sonia
Carnovale, Vincenzo
Colombo, Carla
Raia, Valeria
Blasi, Francesco
Pappagallo, Giovanni
Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
title Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
title_full Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
title_fullStr Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
title_full_unstemmed Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
title_short Use of mucoactive agents in cystic fibrosis: A consensus survey of Italian specialists
title_sort use of mucoactive agents in cystic fibrosis: a consensus survey of italian specialists
topic Reviews
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9169509/
https://www.ncbi.nlm.nih.gov/pubmed/35677472
http://dx.doi.org/10.1002/hsr2.604
work_keys_str_mv AT volpisonia useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists
AT carnovalevincenzo useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists
AT colombocarla useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists
AT raiavaleria useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists
AT blasifrancesco useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists
AT pappagallogiovanni useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists
AT useofmucoactiveagentsincysticfibrosisaconsensussurveyofitalianspecialists